selected publications
-
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Blood advances.
2018
Academic Article
GET IT
Times cited: 47 -
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
Haematologica.
2018
Academic Article
GET IT
Times cited: 10 -
Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.
Leukemia & lymphoma.
2018
Academic Article
GET IT
Times cited: 1 -
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
Clinical lymphoma, myeloma & leukemia.
2018
Academic Article
GET IT
Times cited: 1 -
New therapeutic strategies for high-risk acute myeloid leukemia.
Current opinion in hematology.
2018
Review
GET IT
Times cited: 4